- THE MAGAZINE
- INFO FOR...
- ASI Store
- ASI Top 25
- ASI End User
- Classifieds and Services Marketplace
- Product & Literature Showcases
- List Rental
- Market Trends
- Custom Content & Marketing Services
- ASI Readers' Choice Awards
“Silicone is an ideal matrix material to consider for a wide range of healthcare applications, and our UV cure technology will enable manufacturers to consider a much broader range of ingredients in their silicone mixtures,” said Lynn Colucci-Mizenko, global marketing director for Momentive Performance Materials. “We have conducted successful trials with SSF to optimize the UV curing extrusion process, and the results have confirmed our high expectations.”
The combined focus also takes advantage of SSF’s experience and capabilities in the manufacture of custom silicone components and parts for the medical device industry. Licensed to operate as a drug manufacturing facility and registered with the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research, SSF is planning to expand its API/drug eluting device production into another clean room that will house its own extrusion line and a larger press to meet growing customer demand.
“We see the market for combination devices as a major opportunity for innovation,” said Mark Paulsen, director of Business Development for SSF. “By combining our specialized resources and expertise in medical devices with Momentive Performance Materials’ platform technology, we are well-positioned to help customers explore their most promising possibilities in combination drug products.”
For more information, call (800) 295-2392 or visit www.momentive.com.